Compare VanEck Australian Floating Rate ETF (FLOT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93 (market cap $11.37B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: VanEck Australian Floating Rate ETF is the larger of the two by market cap, and VanEck Australian Floating Rate ETF is more actively traded (2,911,131 versus 1,624,631). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 23 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FLOT | SYRE | |
|---|---|---|
Market Cap | $11.37B | $7.35B |
Volume | 2,911,131 | 1,624,631 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $108.92 |
52-Week Low | $50.72 | $22.18 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.95 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF benefits from floating rate exposure amid Fed tightening, with recent dividends of $0.17-$0.18 paid through October 2026. News highlights concentration risk with 47% bank exposure but positions FLOT as a cash substitute in rising rate environments.
Outlook remains tied to Fed policy, with floating rates offering yield advantage if hikes persist. Key risks include bank sector concentration and rate reversal. Analyst sentiment is cautious due to technical weakness but acknowledges strategic utility for barbell portfolios alongside duration assets.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
